イチバ　シンゴ   Ichiba Shingo   市場　晋吾    所属   医学部 医学科（東京女子医科大学病院）    職種   教授
論文種別	総説
言語種別	英語
査読の有無	査読あり
招待の有無	招待あり
表題	Artificial lungs--Where are we going with the lung replacement therapy?
掲載誌名	正式名：Artificial organs 略　 称：Artif Organs ISSNコード：15251594/0160564X
掲載区分	国外
巻・号・頁	44(11),pp.1135-1149
著者・共著者	Swol Justyna, Shigemura Norihisa, Ichiba Shingo, Steinseifer Ulrich, Anraku Masaki, Lorusso Roberto
発行年月	2020/11
概要	Lung transplantation may be a final destination therapy in lung failure, but limited donor organ availability creates a need for alternative management, including artificial lung technology. This invited review discusses ongoing developments and future research pathways for respiratory assist devices and tissue engineering to treat advanced and refractory lung disease. An overview is also given on the aftermath of the coronavirus disease 2019 pandemic and lessons learned as the world comes out of this situation. The first order of business in the future of lung support is solving the problems with existing mechanical devices. Interestingly, challenges identified during the early days of development persist today. These challenges include device-related infection, bleeding, thrombosis, cost, and patient quality of life. The main approaches of the future directions are to repair, restore, replace, or regenerate the lungs. Engineering improvements to hollow fiber membrane gas exchangers are enabling longer term wearable systems and can be used to bridge lung failure patients to transplantation. Progress in the development of microchannel-based devices has provided the concept of biomimetic devices that may even enable intracorporeal implantation. Tissue engineering and cell-based technologies have provided the concept of bioartificial lungs with properties similar to the native organ. Recent progress in artificial lung technologies includes continued advances in both engineering and biology. The final goal is to achieve a truly implantable and durable artificial lung that is applicable to destination therapy.
DOI	10.1111/aor.13801
PMID	33098217